Stock Taper Sales: Q4 sales reached $1.1 billion, up 8% year-over-year (4% growth excluding acquisitions). Local currency sales growth was 5% overall.
Regional Performance:
Americas: 7% growth (3% from acquisitions)
Europe: 4% growth
Asia/Rest of World: 4% growth, with China at 3%.
Product Performance:
Laboratory: 3% growth
Industrial: 7% growth (2% core growth)
Product Inspection: 7% growth
Food Retail: 19% growth
Service revenue: 8% growth (6% organic).
Margins: Gross margin decreased to 59.8%, impacted by tariffs and foreign currency. Adjusted operating profit was $363 million, with an adjusted operating margin of 32.1%.
Earnings: Adjusted EPS was $13.36, an 8% increase, while reported EPS was $13.98, including a $0.95 discrete tax benefit.
Growth Initiatives: The company is focused on its Spinnaker sales and marketing program and innovation in automation and digitalization.
Product Innovations: Launched new products like the Vero electronic pipette and the X3 Series of X-ray solutions, enhancing their competitive edge in the lab and product inspection markets.
Service Growth: Celebrated achieving $1 billion in service sales, with expectations for continued mid- to high single-digit growth.
2026 Guidance:
Local currency sales growth forecast at approximately 4% (3.5% excluding acquisitions).
Operating margin expected to improve by 60-70 basis points, with adjusted EPS projected between $46.05 and $46.70 (8%-9% growth).
Q1 2026 local currency sales growth expected around 3%, with adjusted EPS guidance of $8.60 to $8.75 (5%-7% growth).
Market Conditions: Cautious outlook for the beginning of 2026 due to geopolitical tensions and customer investment hesitance, although gradual improvements are anticipated throughout the year.
Margin Pressures: Gross margin decline attributed to tariffs (impacting operating profit by $50 million) and unfavorable foreign currency effects.
Market Caution: Customers are expected to be cautious at the start of 2026, with longer deal cycles and subdued demand in certain sectors, particularly in biotech and academia.
Geopolitical Risks: Ongoing geopolitical tensions could impact customer investment decisions and market conditions.
Economic Conditions: Mixed economic conditions in Europe and continued pressure in the chemical sector could hinder growth.
Customer Caution: Management acknowledged customer hesitance despite some positive headlines in pharma and life sciences, indicating a conservative approach to Q1 guidance.
Emerging Markets: Growth expectations for emerging markets (excluding China) remain strong, with a focus on capturing above-average growth.
Bioprocessing: Strong growth in bioprocessing, particularly in the U.S., with optimism for continued momentum in 2026.
Replacement Cycle: The industrial portfolio is expected to benefit from a gradual pickup in the replacement cycle as market conditions stabilize.
Service Opportunities: Continued investment in service is seen as a strategic priority, with significant potential for growth in the serviceable installed base. Overall, Mettler-Toledo demonstrated resilience in a challenging environment, achieving solid financial results while navigating headwinds from tariffs and market caution. The company remains focused on strategic growth initiatives and innovation to drive future performance.
SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT